Miriam Bornhorst, MD
Dr. Bornhorst is a Neuro-Oncologist, the Clinical Director of the Gilbert Neurofibromatosis Institute at Children’s National Medical Center, Medical Director of the Cancer Genetics Program at Children’s National Hospital and an Assistant Professor in the George Washington University Department of Pediatrics. In the clinic, she primarily cares for patients with Neurofibromatosis or other predisposition to develop tumors/cancer. She is the institutional PI for many of the Mek-inhibitor and targeted treatment studies for patients with NF1 at Children’s National. Her initial laboratory research focused on the development of early intervention therapies for optic pathway gliomas in NF. She is now focusing on the identification of novel genomic and metabolomic biomarkers in patients with central and peripheral nervous system tumors, particularly in patients who have cancer predisposition syndromes and brain tumors. She has played an active role in the Children’s National post-mortem program since 2016.
Recent and Notable Publications
Molecularly Targeted Agents in the Therapy of Pediatric Brain Tumors
Bornhorst M, Hwang EI. Molecularly Targeted Agents in the Therapy of Pediatric Brain Tumors. Paediatr Drugs. 2020 Feb;22(1):45-54. doi: 10.1007/s40272-019-00369-z. PMID: 31749132. https://pubmed.ncbi.nlm.nih.gov/31749132/
Somatic Mosaicism of IDH1 R132H Predisposes to Anaplastic Astrocytoma: A Case of Two Siblings
Lee S, Kambhampati M, Almira-Suarez MI, Ho CY, Panditharatna E, Berger SI, Turner J, Van Mater D, Kilburn L, Packer RJ, Myseros JS, Vilain E, Nazarian J, Bornhorst M. Somatic Mosaicism of IDH1 R132H Predisposes to Anaplastic Astrocytoma: A Case of Two Siblings. Front Oncol. 2020 Jan 14;9:1507. doi: 10.3389/fonc.2019.01507. PMID: 32010615; PMCID: PMC6971203. https://pubmed.ncbi.nlm.nih.gov/32010615/
Biological Treatments of Neurofibromatosis Type 2 and Other Skull Base Disorders
Raskin S, Bornhorst M. Biological Treatments of Neurofibromatosis Type 2 and Other Skull Base Disorders. Otolaryngol Clin North Am. 2021 Aug;54(4):789-801. doi: 10.1016/j.otc.2021.05.004. Epub 2021 Jun 11. PMID: 34120747. https://pubmed.ncbi.nlm.nih.gov/34120747/
Liquid biopsy for pediatric central nervous system tumors.
Bonner ER, Bornhorst M, Packer RJ, Nazarian J. Liquid biopsy for pediatric central nervous system tumors. NPJ Precis Oncol. 2018 Dec 17;2:29. doi: 10.1038/s41698-018-0072-z. PMID: 30588509; PMCID: PMC6297139. https://pubmed.ncbi.nlm.nih.gov/30588509/